Q-omics provides the consensus-scored CSF2 profile across patient tissues and cancer cell-line models. CSF2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CSF2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CSF2 RNA expression shows 14,169 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where CSF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSF2 survival associations across molecular data types. CSF2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSF2 RNA expression–survival associations across cancer types. High CSF2 expression shows unfavorable associations in KIRC, HNSC, UVM and KIRP, but favorable associations in SKCM and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CSF2 RNA expression.
This table summarizes CSF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSF2 shows lower tumor expression in LUSC and higher tumor expression in HNSC, THCA, COAD, STAD and KIRP. The HNSC box plot shows higher CSF2 RNA expression in tumor versus normal tissue (log2 FC = +2.820, t-test p < 0.001).
This table shows molecular features associated with CSF2 in patient tissues and cancer cell lines. In patient samples, CSF2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CSF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
